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http://dx.doi.org/10.1016/j.ccell.2015.07.016SUMMARYAlterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute
lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly under-
stood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically
promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem
cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor
agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion
and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids
potentiated the activity of dasatinib inmouse and humanBCR-ABL1ALL, providing an additional therapeutic
option in IKZF1-mutated ALL.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common tumor
and a leading cause of cancer death in the young (Stock, 2010;Significance
The prognosis of high-risk acute lymphoblastic leukemia rema
advent of targeted therapeutic approaches. Deletions or muta
standing of how IKZF1 alteration contribute to leukemia develo
lymphoid lineage, a stem cell-like phenotype, abnormal bonem
inhibitor (TKI) therapy. Using a high-content screen, we show
expression of wild-type IKZF1 and increase responsiveness to
of high-risk ALL and potential therapeutic approaches.
CanInaba et al., 2013). B-progenitor ALL (B-ALL) is more common
than T-lineage ALL and comprises a number of subtypes char-
acterized by constellations of chromosomal alterations, submi-
croscopic deletions, and sequence mutations (Mullighan,ins suboptimal despite contemporary chemotherapy and the
tions of IKZF1 are a hallmark of high-risk ALL, but an under-
pment are lacking. Here, we show that IKZF1 alterations drive
arrow adhesion, and poor responsiveness to tyrosine kinase
that retinoids reverse this phenotype in part by inducing
TKIs. These findings provide insight into the pathogenesis
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2013). Loss-of-function or dominant-negative deletions and mu-
tations of lymphoid transcription factor genes including paired
box 5 (PAX5), IKZF1 (IKAROS), and early B cell factor 1 (EBF1)
are observed in the majority of B-ALL cases (Mullighan et al.,
2007).
IKZF1 alterations are a hallmark of high-risk B-ALL, particu-
larly BCR-ABL1 positive (Ph+) ALL (Mullighan et al., 2008) and
Ph-like ALL, which is characterized by a range of genetic alter-
ations driving cytokine receptor and kinase signaling (Den
Boer et al., 2009; Mullighan et al., 2009; Roberts et al.,
2012, 2014). IKZF1 alterations include deletions that result in
loss of expression of wild-type (WT) IKZF1 (IK1) and focal de-
letions or sequence mutations that alter IKZF1 function. A
common deletion involving exons 4–7 results in expression
of the IK6 isoform that lacks the N-terminal DNA-binding
zinc fingers, but retains the C-terminal zinc fingers responsible
for dimerization (Mullighan et al., 2008). IK6 has dominant
negative effects, in part by mislocalizing WT IKZF1 from the
nucleus to the cytoplasm. Sequence mutations commonly
involve zinc finger residues that mediate DNA binding (Mul-
lighan et al., 2009). IKZF1 alterations are also common in
chronic myeloid leukemia (CML) at progression to lymphoid
blast crisis, but are rare at chronic phase and progression to
myeloid blast crisis, suggesting a central role in determining
disease lineage and progression to acute leukemia (Mullighan
et al., 2008). Additional genetic alterations are also observed in
BCR-ABL1 lymphoid leukemia, most commonly deletion of
CDKN2A/B (INK4/ARF) in approximately 50% of cases (Mul-
lighan et al., 2008).
IKZF1 alterations are associated with poor outcome in Ph-
positive ALL, despite the advent of tyrosine kinase inhibitor
(TKI) therapy (Martinelli et al., 2009; van der Veer et al., 2014)
and Ph-negative B-ALL (Mullighan et al., 2009; Kuiper et al.,
2010). Consequently, new therapeutic approaches to improve
the outcome of IKZF1-mutated ALL are required. However, a
detailed understanding of the relative roles of IKZF1 alterations
and concomitant genomic alterations in lymphoid leukemogen-
esis and resistance to therapy is lacking. IKZF1 is required for
the specification of the lymphoid lineage (Georgopoulos et al.,
1994) by activating a lymphoid transcriptional network, while re-
pressing stem cell-, myeloid-, and erythroid-specific genes
(Yoshida et al., 2010). Ikzf1 haploinsufficiency accelerates the
onset of BCR-ABL1 lymphoid leukemia (Virely et al., 2010) and
deletions of selected N-terminal zinc fingers in B cells results in
stromal adhesion and progression to acute leukemia in mice
(Schjerven et al., 2013; Joshi et al., 2014). However, these
studies do not fully recapitulate the genomic alterations in human
IKZF1-mutated leukemia (including BCR-ABL1, expression of
IK6, and CDKN2A/B deletion), nor do they directly model the
role of IKZF1 alterations in determining disease lineage and
responsiveness to TKI therapy.
Here, we describe mouse models of Ikzf1-mutated, Ph+ ALL.
We have used these models to examine the effects of different
Ikzf1 alterations, including haploinsufficiency and/or expression
of IK6, and Arf loss, on disease lineage and responsiveness to
TKI therapy. We examine the role of Ikzf1 alterations on the
acquisition of hematopoietic stem cell-like features and have
used these models as a platform of drug discovery to identify
agents that enhance responsiveness to TKI therapy.344 Cancer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier InRESULTS
IKAROS Alterations in Human BCR-ABL1 B-ALL
We previously reported a prevalence of IKZF1 alterations in
approximately 15% of childhood ALL and over 80% of Ph+ ALL
(Mullighan et al., 2008; Zhang et al., 2011). However, the preva-
lence of IKZF1 alterations has differed between studies. We
examined IKZF1 status in large cohorts of childhood and adult
Ph-positive and negative ALL (Figure 1A; Table S1) (Roberts
et al., 2014). Therewere25%ofchildhoodand44%of youngadult
precursorBcell ALLcases that hadalterationsof IKZF1. Exon 4–7
(IK6) deletionswere present in 22.9%of B-ALL cases and biallelic
alterations in 13.2% of cases. IKZF1 sequence mutations were
observed in 2.6% of childhood and 3.4% of young adult ALL.
Many sequence alterationsweremissensemutations in theN-ter-
minal zinc fingers at or near residues known to be critical for DNA
binding (Cobb et al., 2000) and are thus likely to be lossof function
and/or exert dominant negative effects (Figure 1B).
To compare the effects of point mutations to IK6, we ex-
pressed six different IKZF1 point mutant alleles, as well as WT
IKZF1 and IK6 in Arf/ BCR-ABL1-expressing pre-B cells.
These experiments were performed in Arf/ cells; although
Cdkn2a encodes both p19Arf and p16Ink4a, prior studies have
shown loss of Arf, but not Ink4a, promotes the development of
BCR-ABL1 ALL (Kamijo et al., 1997; Williams et al., 2006; Signer
et al., 2010). Enforced expression of WT IKZF1 was not tolerated
and resulted in cell death. In contrast, all Ikzf1 point mutant al-
leles resulted in perturbed subcellular localization of the protein
(Figure 1C). Endogenous IKZF1 exhibited punctate nuclear
staining, whereas IK6 or IKZF1 point mutant alleles exhibited
cytoplasmic or perturbed nuclear localization (Figure 1C).
Thus, like IK6 (Nishii et al., 2002), the IKZF1 sequence mutations
observed in human ALL result in cellular mislocalization and may
also perturb IKZF1 function.
Cooperativity of Ikzf1 and Arf Alterations in BCR-ABL1
Lymphoid Leukemogenesis
To examine the relative contributions of IKZF1 and Arf alterations
in leukemogenesis, we used unfractionated, lineage negative
(lin) and pre-B cell retroviral bone marrow (BM) transplant
models of BCR-ABL1 leukemia. Consistent with prior data (Virely
et al., 2010), heterozygosity for an Ikzf1 null allele increased the
penetrance and reduced latency of pre-B cell ALL in both whole
BM and pre-B cell transplant models (Figures 2A and 2B). The
leukemias were of pre-B cell lineage (CD43+, B220+, CD19+,
BP-1+, and IgM; Figure S1A). There was no expansion of
lymphoid progenitors in Ikzf1+/ marrow (Figure S1B), and
Ikzf1+/ mice did not develop leukemia in the absence of
BCR-ABL1, suggesting that loss of IKZF1 does not promote
leukemogenesis by expanding the pool of lymphoid progenitors
susceptible to transformation.
Human Ph+ ALL tumors commonly harbor recurring DNA copy
number alterations in addition to deletion of IKZF1, including de-
letions ofCDKN2A/B, PAX5, EBF1, andMEF2C (Mullighan et al.,
2008, 2009). Using a comparative genomic hybridization micro-
array with dense tiling of targets of genetic alteration in human
B-ALL (Table S2), we identified deletions also observed in human
B-ALL, including deletions of Ebf1 and Cdkn2a/b, but not Ikzf1
(Figure S1C). These data support the notion that IKZF1c.
Figure 1. IKZF1 Alterations in Human B-ALL
(A) Distribution of IKZF1 alterations in human Ph+ (left, n = 89) and Ph- (right, n = 405) B-ALL.
(B) Point mutations found in human B-ALL. The highlighted mutations were modeled in Arf/ BCR-ABL1-expressing pre-B cells studied in (C).
(C) WT IKZF1, IK6, and six IKZF1 point mutants were expressed in Arf/ BCR-ABL1-expressing pre-B cells (scale bars represent 2 mm).
See also Table S1.haploinsufficiency promotes tumorigenesis, but this process in-
volves the sequential acquisition of additional genetic alter-
ations, including second hits disrupting transcriptional regulation
of lymphoid development.
The lineage of BCR-ABL1 leukemia has been attributed to the
cellular target of transformation (McLaughlin et al., 1987; Daley
et al., 1990), but the importance of cooperating genetic alter-
ations has not been formally examined. To examine the role of
Ikzf1 and Arf alterations in determining disease lineage, we
adopted a retroviral BM transplant model of BCR-ABL1 leuke-Canmia, in which expression of BCR-ABL1 in lineage-negative he-
matopoietic progenitors robustly induces myeloproliferative dis-
ease that recapitulates CML (Daley et al., 1990). As expected,
WT BM expressing BCR-ABL1 resulted in a fully penetrant
myeloid leukemia (Figures 2C and S1D). In combination with
IK6, BCR-ABL1 drove eithermyeloid or B-lymphoid disease (Fig-
ures 2C andS1D). On anArf/ background, BCR-ABL1 resulted
in 29% myeloid tumors and 71% B-lymphoid tumors; with IK6,
BCR-ABL1 uniformly induced B-ALL (Figures 2C and S1D). A
recipient of Arf/ BCR-ABL1 cells developed a bilineal tumorcer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier Inc. 345
Figure 2. Perturbation of IKZF1 Drives a Lymphoid Leukemia with Less Responsiveness to TKI Therapy
(A) Unmanipulated BM from WT or Ikzf1+/ mice transduced with p185 BCR-ABL1 expressing retrovirus and immediately transplanted into lethally irradiated
recipients. The statistical significance was assessed by log rank Mantel-Cox (***p < 0.0005 and n = 10 mice per group).
(B) Transplantation of in vitro-derived BCR-ABL1 transformed pre-B cells into sublethally irradiated recipients. The statistical significance was assessed by log
rank Mantel-Cox (***p < 0.0005 and n = 10 mice per group).
(C) Summarized leukemia lineage data from lin BM transplant experiments (see also Figure S1) (X2 p = 0.0029 and nR 6 mice per group).
(D) Representative flow cytometric analysis of tumors derived from p185 BCR-ABL1 transduced lin BM cells to determine disease lineage.
(E) In vivo quantification of luciferase activity, representing disease burden, in mice transplanted with pre-B cells of the defined genotypes (WT, Arf/, or Ikzf+/)
transduced with BCR-ABL1-ires-luciferase and empty vector (MIG) or IK6. The raw data points ± SD are plotted. The treatment was started when the average
luminescence was greater than 2 3 107 photons/second, indicating a substantial and similar disease burden at the start of therapy between genotypic groups
shown in (F)–(H) and Table 1.
(F) Kaplan-Meier survival curves of vehicle or dasatinib-treated mice inoculated with pre-B cells derived from WT BM described in (E).
(G) Kaplan-Meier survival curves of vehicle or dasatinib-treated mice inoculated with pre-B cells derived from Ikzf+/ BM described in (E).
(H) Kaplan-Meier survival curves of vehicle or dasatinib-treated mice inoculated with pre-B cells derived from Arf/ BM described in (E). The statistical sig-
nificance was accessed by log-rank Mantel-Cox test in (F)–(H) (**p < 0.005 and n = 8 mice per group).
See also Figure S1 and Table S2.with both myeloid and lymphoid (Figures 2D and S1E). All other
tumors were either myeloid or lymphoid by immunophenotype
and morphology (Figures 2D and S1F), and were retransplant-
able maintaining immunophenotypic fidelity to the primary tumor
(Figure S1E). These results indicate that both IK6 and loss of Arf
shift differentiating hematopoietic precursors toward a lymphoid
fate during BCR-ABL1-driven leukemogenesis.346 Cancer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier InIkzf1 Alterations Reduce Responsiveness of BCR-ABL1
ALL to Dasatinib
Wenext examined the effects of Ikzf1haploinsufficiency, IK6, and
Arf loss on responsiveness to TKI therapy. To establish ALL
models of each Arf/Ikzf1 genotype with equivalent tumor burden
at the commencement of therapy, 2 3 105 pre-B cells from WT,
Arf/, or Ikzf+/ mice expressing MSCV-BCR-ABL1-ires-lucc.
Table 1. Efficacy ofDasatinib onVarious Ikzf1-AlteredBCR-ABL1
Leukemic Cells In Vivo
Genetic
Combination
Day Treatment
Started
Median Survival (Post-Injection)
Untreated Dasatinib
WT MIG not applicable 51 not applicable
WT IK6 14 23 51.5
Ikzf+/ MIG 14 23 44
Ikzf+/ IK6 10 17 31.5
Arf/ MIG 7 15 24
Arf/ IK6 7 13 17and either MSCV-IK6-IRES-GFP (MIG-IK6) or empty vector
(MIG) were inoculated into sublethally irradiated WT recipients.
Dasatinib or vehicle was commenced at equivalent tumor
burden as determined by bioluminescent imaging (Figure 2E).
ALL lacking Ikzf1 or Arf alterations was not modeled due to
incomplete penetrance and highly variable latency.
Ikzf1 haploinsufficiency and IK6 both reduced disease latency
in a synergistic fashion (Ikzf1+/+ + IK6 versus Ikzf1+/ + IK6 p <
0.0001; Table 1; Figures 2F–2H). Expression of IK6 resulted in
a reduced response to dasatinib treatment, also in a synergistic
manner with Ikzf1 haploinsufficiency (Figures 2F–2H). The
reduced effect of dasatinib in Ikzf1-altered leukemias was not
due to impaired inhibition of ABL1 (as measured by STAT5 and
CRKL phosphorylation; Figure S1G) or the acquisition of ABL1
tyrosine kinase domain mutations (data not shown).
Increased Adhesion of Ikzf1-Altered BCR-ABL1
Pre-B Cells
We next examined the growth kinetics and phenotypic proper-
ties of BCR-ABL1 pre-B cells of various Ikzf1 and Arf genotypes
(WT, Arf/, Ikzf1+/, and Ikzf1+/;Arf+/ with and without IK6).
Both Ikzf1 haploinsufficiency and expression of IK6 reduced
doubling times (Figure S2A).
We observed striking effects of all Ikzf1 alterations on intercel-
lular adhesion (Figure 3A). Regardless of genetic background,
BCR-ABL1 pre-B cells harboring Ikzf1 alterations exhibited
marked changes in their morphology with adherence in
sphere-like aggregates in vitro. This was observed for Ikzf1 hap-
loinsufficiency, expression of IK6 or zinc finger point mutant
alleles, and small hairpin (sh)RNA-knock down of Ikzf1 (Fig-
ure S2B). Knock down of Ikzf3 (AIOLOS), an IKAROS family
member that with IKZF1 is part of the Mi-2/nucleosome remod-
eling and deacetylase (NuRD) complex (Zhang et al., 2012b), re-
sulted in similar cellular aggregation (Figure S2B, XIV). Knock
down of Ikzf2 (HELIOS), that does not share a role in the NuRD
complex and is not expressed in pre-B cells, had no effect.
To assess whether the increased adhesion of Ikzf1-altered
BCR-ABL1 pre-B cells conferred an advantage in homing and
engraftment in the BM niche, we transplanted 2 3 105 Arf/
pre-B cells expressing BCR-ABL1 and either IK6-MIG or MIG
and harvested calvaria at 24, 48, and 72 hr post-injection to track
the infiltration of GFP-labeled cells in the BM cavities utilizing
multiphoton microscopy. By 48 hr sufficient cells were visible
in each group to enable accurate quantitation of engraftment
(Figure S2C). No quantitative differences in homing were de-
tected, however, IK6-expressing cells adopted spindle-likeCanmorphology, with adherence to and infiltration of surrounding
BM stroma (Figure 3B). To assess localization in the BM niche,
we repeated this experiment using Prrx1-Cre;Ai9 recipient
mice, which express tdTomato inmesenchymal stem cells, oste-
oblasts, and CXCL12-abundant reticular cells (Greenbaum et al.,
2013), followed by in vivo antibody-based marking of the BM
vasculature. This showed localization of leukemic cells adjacent
to perivascular mesenchymal cells and SCA-1+ arteriolar endo-
thelial cells (Figure 3C). This stromal adherence in vivo was reca-
pitulated in vitro by measuring adherence to the fibronectin,
which showed increased adherence of IK6-expressing cells,
comparable to purified murine hematopoietic stem cells
(mHSCs), after short-term incubation (Figure 3D).
Characterization of the Adhesive Phenotype
of Ikzf1-Altered Leukemia
We next performed transcriptomic and proteomic profiling of
Arf/ BCR-ABL1 pre-B cells with or without expression of IK6
and immunophenotyping of a large cohort of human Ph+ ALL
cases of known IKZF1 genotype (Table S5). These analyses
showed highly significant correlation of the transcriptomic and
proteomic signatures of BCR-ABL1 IK6 versus non-IK6 leuke-
mias, with gene set enrichment analysis p and FDR
q values < 0.0001 for enrichment of the expression signature in
the proteomic signature. IK6-expressing leukemic cells showed
overexpression of multiple adhesion molecules implicated in
leukemic and stem cell adherence, including thymocyte differen-
tiation antigen 1 (THY1, CD90), L-selectin (SELL), and the THY1
ligand integrin alpha 5 (ITGA5) (Saalbach et al., 2005), as well as
other genes involved in THY1 integrin signaling, including protein
kinase 2 (PTK2; or focal adhesion kinase, FAK) and PTK2B (Fig-
ures 3E, 3F, S2D, and S2E; Tables S3 and S4). THY1 is a glyco-
sylphosphatidylinositol (GPI)-anchored glycoprotein involved in
adhesion (Rege and Hagood, 2006) and integrin signaling
(Barker and Hagood, 2009). THY1 is expressed by thymocytes,
hematopoietic stem cells (Craig et al., 1993; Mayani and Lans-
dorp, 1994; Notta et al., 2011), and stem cell-enriched popula-
tions in non-BCR-ABL1 leukemia (Lamkin et al., 1994; Yamazaki
et al., 2009), but not normal B cells. THY1 and ITGA5 are both ex-
pressed at high levels in mouse and human HSCs (Figures S2F
and S2G), and mouse and human HSCs were highly adherent
to fibronectin in vitro (Figures 3D and S2H). Thy1 is a target of
IKZF1 transcriptional repression (Zhang et al., 2012b). Analysis
of existing chromatin immunoprecipitation (ChIP) sequencing
data (Ferreiro´s-Vidal et al., 2013) and ChIP-PCR of BCR-ABL1
Arf/ pre-B cells showed that Thy1, Sell, Cd28, and Itga5 are
IKZF1 targets in primary mouse pre-B cells (Figures S2I and
S2J).
All BCR-ABL1 pre-B cell lines harboring an Ikzf1 alteration dis-
played increased THY1 expression relative to controls (Figures
3G and S2K). IK6-expressing tumor cells from both lin and
pre-B cell experiments, and BCR-ABL1 cells following RNAi-
mediated Ikzf1/3 knockdown showed increases of THY1 expres-
sion (Figures 3E–3G and S2K–S2M). Immunophenotyping of 98
human ALL samples showed higher THY1 expression in
IKZF1-altered BCR-ABL1 B-ALL cases compared to those lack-
ing IKZF1 alterations and non-Ph+ cases (Figure 3H; Table S5).
To examine the role of adhesion molecule upregulation, we
incubated Arf/ BCR-ABL1 IK6 pre-B cells with a neutralizingcer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier Inc. 347
Figure 3. IKZF1 Alterations Induce Aberrant Adhesion in BCR-ABL1 Leukemic Cells
(A) Suspension cultures of Arf/ BCR-ABL1 (p185) pre-B leukemic cells showing adherent growth in IK6 expressing cells in vitro (scale bars represent 100 mM).
(B) Calvarial imaging of mice transplanted with Arf/ BCR-ABL1-transduced pre-B cells expressing MIG or IK6-GFP in vivo (white arrows indicate cells with
marked change in pre-B cell morphology; scale bars represent 20 mM).
(C) Calvarial imaging of Arf/BCR-ABL1 IK6-GFP leukemic cells in Prrx1-Cre;Ai9 tomato mice showing associations with the PRRX1+ perivascular stromal cells
(left) and in vivo-labeled SCA-1+ arterioles (right) in the BM niche (scale bars represent 20 mM).
(D) Arf/ BCR-ABL1 IK6-expressing cells are more adherent to fibronectin monolayers in vitro, comparable to mouse HSC. The data are means ± SD (*p < 0.05,
***p < 0.0005, and n = 3 biological replicates).
(E) The adherent phenotype of IK6-expressing Arf/ BCR-ABL1 pre-B cells is accompanied by increased expression of adhesion markers compared to empty
vector controls, as determined by mRNA-seq. The data are means ± SD (***p < 0.0005 and n = 4 biological replicates per group).
(F) Proteomic analysis by tandemmass tag based mass spectrometry confirms increased protein expression of adhesion markers in IK6-expressing pre-B cells.
The data are means ± SD (***p < 0.0005, **p < 0.005, *p < 0.05, and n = 3 biological replicates per group).
(G) Flow cytometric analysis for THY1 in cultured WT, Ikzf1+/, and Arf/ BCR-ABL1-transduced cells expressing empty vector or IK6. The data are means ± SD
(**p < 0.005, *p < 0.05, and n = 3 biological replicates).
(H) Increased expression THY1 (CD90) by immunophenotypic analysis of human BCR-ABL1 (Ph+) and IKZF1-mutated leukemias. The data are means ± SD (**p <
0.005 and 98 human cases were analyzed). See also Table S5.
(legend continued on next page)
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Figure 4. IKZF1 Alterations Induce Stem Cell-like Features in BCR-ABL1 Leukemic Cells
(A) GSEA analyses of Arf/ BCR-ABL1 MIG versus IK6-expressing pre-B cells showing IK6 expression is associated with acquisition of a stem-like gene
expression program. A full list of significantly enriched gene sets is provided in Table S3.
(B) IKZF1 perturbation and Arf loss synergistically result in enhanced self-renewal of BCR-ABL1-expressing pre-B cells, as shown by the ability of single cell
cultures to form colonies. The data are means ± SD (***p < 0.0005 and n = 3 biological replicates performed in triplicate).
(C) Single cell replatingswere sustained over serial passages in the immortalArf/ lines. The data aremeans ± SD (*p < 0.05 and n = 4 technical replicates, 96well
plates).
(D) A neutralizing THY1 antibody attenuates the colony-forming ability of Arf/ BCR-ABL1 IK6 pre-B cells. The data are means ± SD (**p < 0.005 and n = 3
biological replicates).anti-THY1 antibody, which abrogated the clustering phenotype,
whereas an antibody directed to B220 and an IgG control had no
effect (Figure 3I). shRNA-mediated knock down of THY1, SELL,
or ITGA5 also disrupted cellular aggregation in vitro (Figures 3J
and S2N). Conversely, overexpression of THY1, SELL, or
ITGA5 alone in Arf/ BCR-ABL1-expressing pre-B cells was
sufficient to induce clustering (Figures 3K and S2O), demon-
strating that THY1, SELL, and ITGA5 mediate adhesion of
IKZF1-altered cells.
Ikzf1Alterations Result in Acquisition of a StemCell-like
Phenotype
The gene expression profile of IK6-expressing BCR-ABL1 Arf/
pre-B cells was significantly enriched for gene sets upregulated
in human Ph+ B-ALL, transcriptional targets of IKZF1, and gene
sets representative of human embryonic (Wong et al., 2008), he-
matopoietic (Doulatov et al., 2010; Novershtern et al., 2011), and
leukemic (Zhang et al., 2012a) stem cells (Figure 4A). This is
consistent with previous observations in human IKZF1-altered
ALL (Mullighan et al., 2009) and suggests that IKZF1 alterations
impair hematopoietic development and confer stem cell-like fea-
tures. To investigate this, we examined the single cell colony(I) Cellular adherence of Arf/ BCR-ABL1 IK6-expressing pre-B cells is abrogated
bars represent 100 mM).
(J) Cell aggregation is also attenuated by shRNA knock down of Thy1, Sell, or Itg
(K) Overexpression of THY1, SELL, or ITGA5 resulted in cellular aggregation (sca
Canforming potential of WT, Ikzf1+/, and Arf/ BCR-ABL1 pre-B
cell lines with and without IK6 as a measure of self-renewal. In
all genetic backgrounds, Ikzf1-alterations conferred increased
clonogenicity (Figure 4B). Serial replating of the Arf/ groups
demonstrated that IK6-expressing cells maintain a consistent
level of clonogenicity over 8 weeks, while cells expressing empty
vector decrease the number of colonies formed over time (Fig-
ure 4C). WT cultures could not be maintained more than two se-
rial platings due to loss of ARF. The addition of THY1-neutralizing
antibody to themedia prior to single cell sorting reduced the abil-
ity of IK6-expressing cells to form colonies (Figure 4D).
Retinoid X Receptor Agonists Induce IKZF1 Expression
and Ameliorate the Effects of Ikzf1 Alterations
As IKZF1 alterations induce stem cell and adhesive properties,
and are associated with poor response to TKI therapy in human
ALL, we performed a drug screen to identify agents that reverse
this stem cell-like phenotype and enhance TKI sensitivity. We
used high-throughput microscopy to measure the clustering of
IK6-expressing Arf/ BCR-ABL1 pre-B cells with the aim of
identifying compounds that abolish their sphere-forming capac-
ity without directly affecting viability, although direct cytotoxicityin vitro by anti-THY1 antibody, but not B220 and IgG control antibodies (scale
a5 (scale bars represent 100 mM).
le bars represent 100 mM). See also Figure S2 and Tables S3, S4, and S5.
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Figure 5. Retinoids Disrupt Cellular Aggregation and Reverse the Stem Cell-like Features of BCR-ABL1 Leukemic Cells
(A) Suspension cultures of Arf/BCR-ABL1 IK6-expressing cells exposed to DMSO or retinoids at 1 mM for 72 hr. Each drug abolishes adherent growth induced
by IK6 (scale bars represent 100 mM).
(B) In vitro growth kinetics of DMSO or retinoid-treated Arf/ BCR-ABL1 IK6-expressing cells. The data are means ± SD (n = 3 biological replicates).
(C) Retinoid treatment arrests Arf/ BCR-ABL1 IK6-expressing pre-B cells at the G0/G1 phase of the cell cycle. The data are means ± SD (*p < 0.05 and n = 3
biological replicates performed in triplicate). Bex, bexarotene; Carb, carbacyclin.
(D) Flow cytometry of retinoid-treated Arf/BCR-ABL1 IK6-expressing pre-B cells shows decreased CD43 expression and increased CD25 levels. The data are
means ± SD (**p < 0.005 and n = 3 biological replicates performed in triplicate).
(E) Relative expression of aberrantly expressed adhesion molecules in Arf/ BCR-ABL1 IK6-expressing pre-B cells following retinoid treatment, as determined
by mRNA-seq. The data are means ± SD (***p < 0.0005, **p < 0.005, and n = 4 biological replicates).
(F) Retinoid treatment attenuates the self-renewal of Arf/ BCR-ABL1 IK6-expressing pre-B cells as demonstrated by single cell colony forming ability. The data
are means ± SD (***p < 0.0005 and n = 3 biological replicates performed in triplicate 96 well plates).
(G) In vivo bexarotene (bex) treatment reversed the adherent phenotype of Arf/BCR-ABL1 IK6-GFP cells in the calvarial BM niche (scale bars represent 20 mM).
(H) Luciferase quantification of vehicle or bex-treatedmice 14 days after inoculation with 23 105Arf/ p185 IK6 leukemic cells. The daily vehicle or 45mg/kg oral
bex treatment commenced at the time of transplant. The raw data points ± SD are plotted (***p < 0.0005 and n = 5 mice per group).
See also Figure S3 and Tables S6 and S7.was also measured (Figures S3A–S3C). Disruption of clustering
suggested that a drugmight reverse the stem cell-like character-
istics induced by IKZF1 alteration, and might augment respon-
siveness to existing therapy.
An initial screen of 356 compounds currently in clinical use or
trials (Table S6) identified bexarotene as the agent that most
potently inhibited cellular aggregation (Figure 5A). Bexarotene
is a synthetic retinoid that activates retinoid X receptors
(RXRs). A secondary screen using 127 nuclear hormone receptor
effectors (Table S6) identified carbacyclin, all-trans retinoic acid
(ATRA), 9-cis RA, and 13-cis RA as potent inhibitors of cellular
aggregation. Carbacyclin is a peroxisome proliferator-activated
receptor (PPAR) agonist, whereas ATRA and 9-/13-cis RA acti-
vate RA receptors (RARs), although all have promiscuous activity
for multiple receptors. All compounds identified converge on the350 Cancer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier Inretinoid pathway, whereby RXRs, RARs, and PPARs can inter-
changeably heterodimerize to transcriptionally activate target
genes containing appropriate response elements (Altucci et al.,
2007). Rara, Rarg, Rarres, Rxra, Rxrb, Ppard, and Ppargc1b
were expressed inArf/BCR-ABL1 pre-B cells, all of which har-
bor IKZF1 binding sites, with significant upregulation ofRxra, en-
coding RXR alpha, in IK6 expressing cells (Figures S3D and S3E).
As these agents exhibit cross reactivity for the different retinoid
receptors, we also treated IK6-expressing Arf/ BCR-ABL1
pre-B cells with RXR-specific agonist LG100268 (LG) and the
RAR-specific agonist, AGN-195183 (AGN). LG abrogated the
clustering phenotype in vitro, whereas AGN and the SELL inhib-
itor rivipansel had no effect on adhesion (Figure S3F). In addition,
connectivity map analysis (Lamb et al., 2006) identified the gene
expression signature of 13-cis-RA as negatively enriched in thatc.
Figure 6. Retinoids Induce IKZF1 Expression, but Not IK6, in BCR-ABL1 Leukemic Cells
(A) Proportion of Ikzf1 transcripts from alternate transcriptional start sites, as determined by mRNA-seq in Arf/ p185-expressing pre-B cells. The data are
means ± SD (***p < 0.0005, **p < 0.005, *p < 0.05, and n = 4 biological replicates).
(B) Ikzf1mRNA levels are increased after retinoid treatment in Arf/ p185 MIG or IK6 pre-B cells. The data are means ± SD (***p < 0.0005, **p < 0.005, *p < 0.05,
and n = 4 biological replicates).
(C) Western blot of bexarotene-treated murine Arf/ BCR-ABL1 IK6-expressing pre-B cells.
(D) Western blot of retinoid-treated human CDKN2A-deleted (Arf null) BCR-ABL1+ IK6-expressing B-ALL cells.
(E) RT-PCR analysis of retinoid-treated human BCR-ABL1 IK6 B-ALL cells for IKZF1 and IK6 transcripts.
(F) Immunofluorescence for IKZF1 in CDKN2A-deleted (Arf null) BCR-ABL1+ IK6-expressing B-ALL cells (scale bars represent 5 mm).
(G) Immunofluorescence for IKZF1 in murine Arf/ BCR-ABL1 MIG (top) and IK6-exressing (bottom) pre-B cells (scale bars represent 2 mm).
(H) Overexpression of IKZF1 in Arf/ BCR-ABL1 IK6 pre-B cells abrogates cellular adhesion in vitro (scale bars represent 100 mm).
(I) Overexpression of IKZF1 in Arf/ BCR-ABL1 IK6 pre-B cells downregulates THY1 and ITGA5 (as determined by flow cytometry). The data are means ± SD
(***p < 0.0005, **p < 0.005, and n = 3 technical replicates).
See also Figure S4.of Arf/ BCR-ABL1 MIG-IK6 versus MIG leukemia, further sup-
porting the importance of this pathway in Ikzf1-altered ALL (p =
0.0048 and specificity = 0.0079; Table S7).
Each non-specific retinoid abrogated sphere formation of
Arf/BCR-ABL1 IK6-expressing pre-B cells (Figure 5A), and ar-
rested cell proliferation (Figure 5B) at the G0/G1 phase of the cell
cycle (Figure 5C), with minimal apoptosis (Figure S3G). With the
exception of carbacyclin, this was associated with partial matu-
ration, with reduced CD43 and increased CD25 expression (Fig-
ure 5D), and on transcriptomic analysis, reversal of the hemato-
poietic stem cell state and induction of a B cell differentiation
program (Figure S3H). THY1 and CD28 expression was reduced
after 72 hr of treatment in vitro, with drug-dependent effects on
ITGA5 and SELL levels (Figure 5E). Expression of the down-
stream integrin signaling mediator PTK2B was also reduced by
each compound (data not shown). All retinoids profoundly
decreased the colony-forming potential of IK6-expressing pre-
B cells (Figure 5F). In calvarial BM imaging experiments, in vivoCantreatment with bexarotene at 0, 24, and 48 hr post-transplant
restored the spherical, non-adherent phenotype of transplanted
Arf/ BCR-ABL1 IK6-expressing pre-B cells (Figure 5G). In
addition, leukemic burden was significantly decreased in mice
treated with bexarotene (Figure 5H).
IKZF1 has alternate non-coding first exons, and the promoter,
50 untranslated region, and gene body harbor multiple putative
RA response elements (RARE; Figure S4A). Ikzf1 is a direct target
of RXR signaling, as determined by ChIP-PCR in Arf/ BCR-
ABL1 IK6 pre-B cells. No enrichment was observed for RAR
binding at the Ikzf1 locus (Figure S4A). Retinoid treatment re-
sulted in induction of WT IKZF1, but not IK6 expression from
the first non-coding exon in both mouse and human leukemic
cells as determined by RNA-sequencing (seq) (Figures 6A and
6B). Western blotting, RT-PCR, and immunofluorescence
confirmed selective induction of WT IKZF1, but not IK6 by reti-
noids, and partial relocalization of IKZF1 to the nucleus in IK6-ex-
pressing cells (Figures 6C–6G). Moreover, 1,745 (85%) of 2,061cer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier Inc. 351
genes differentially expressed in Arf/ BCR-ABL1 IK6 cells
following bexarotene treatment were IKZF1 targets (Ferreiro´s-
Vidal et al., 2013), compared to 40% of non-differentially ex-
pressed genes (p < 23 1016), supporting the notion that induc-
tion of IKZF1 directly contributes to the effects observed upon
retinoid treatment. Multiple RAREs within the genomic region
of IKZF1 deleted in the IK6 allele showed significant enrichment
for RXR binding, particularly after treatment with the RXR-spe-
cific agonist LG (Figure S4A). In addition, the IKZF1 locus has a
putative intragenic enhancer within the region of IK6 deletion
marked by H3K27 acetylation in K562 (BCR-ABL1+ IKZF1 WT
cells; Figure S4B) that has been shown to interact with the
IKZF1 promoter through Chromatin Interaction Analysis
Paired-End Tags only in K562 among the six ENCODE cell lines
(Li et al., 2012), suggesting that this region that is lost in IK6-
deleted cases influences regulation of IKZF1 expression.
To test if directly increasing IKZF1 expression levels recapitu-
lates the effects of retinoids, we enforced expression of IKZF1 in
Arf/ BCR-ABL1 pre-B cells with or without expression of IK6.
Enforced expression of IKZF1 is not tolerated by Ikzf1 WT cells
and results in apoptotic cell death (Figure 1C). In contrast,
IKZF1 expression in IK6-expressing cells did not suppress prolif-
eration or cause cell death (Figure S4C), but resulted in attenua-
tion of aggregation accompanied by a decrease in THY1 and
ITGA5 expression (Figures 6H and 6I). Therefore, in IKZF1-
altered cells, the induction of WT Ikzf1 by retinoids leads to
abrogation of the adherent phenotype, but cell cycle arrest and
differentiation are caused by retinoid-related, non-IKZF1-depen-
dent mechanisms. In contrast, bexarotene did not significantly
reduce proliferation in mouse BCR-ABL1 leukemic cells lacking
Arf/Ikzf1 alterations (Figure S4D). Reduced proliferation and
abrogation of clustering was observed in non-BCR-ABL1 human
leukemic cells with IKZF1 alterations, including Ph-like ALL cells
expressing PAG1-ABL2 or harboring EPOR rearrangements
(Figure S4D and S4E), as has been reported for retinoids in
non-BCR-ABL1 ALL cells (Zhang et al., 2002; Lin et al., 2007).
Retinoids Increase Responsiveness of Ikzf1-Altered
Leukemias to TKIs
Using in vitro viability assays with the drug added at the time of
cell plating, bexarotene significantly increased responsiveness
to dasatinib in IK6-expressing Arf/ BCR-ABL1 IK6 pre-B cells
(data not shown). Response to dasatinib was also improved in
Arf/ BCR-ABL1 pre-B cells lacking IK6, consistent with reti-
noid induction of IKZF1 expression in non-IK6 expressing cells
causing cell cycle arrest and subsequent death (Figures 1C
and S4C).
We examined the combinatorial and single-agent effects of
bexarotene, dasatinib, and additional cytotoxic agents used in
ALL therapy, L-asparaginase and dexamethasone, in mice
transplanted with Arf/ BCR-ABL1 pre-B cells with or without
IK6 expression. In contrast to L-asparaginase and dexametha-
sone (Boulos et al., 2011), bexarotene monotherapy resulted in
significant benefit without detectable toxicity (Figure 7A and
S5A). Dasatinib monotherapy increased survival with inferior
responsiveness in the IK6 group (Figure 7A). The combination
of dasatinib and bexarotene resulted in the greatest survival
advantage, with a near doubling of survival time in IK6 tumors
compared to dasatinib monotherapy. Thus, bexarotene en-352 Cancer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier Inhances efficacy of TKI therapy in Ph+ tumors regardless of
Ikzf1 status, but with the greatest potentiation observed in
Ikzf1-altered tumors.
To test the activity of retinoids in human leukemic cells, we es-
tablished xenografts of Ph+ ALL that faithfully recapitulate a
range of IKZF1 genotypes. The tumors harbored homozygous
deletion of CDKN2A/B (i.e., INK4/ARF-null) and had deletions
or sequence mutations of IKZF1 (IKZF1 D4–7, D2-7, or
R502W). Xenografts were treated with dasatinib in combination
with bexarotene, ATRA, or the FAK inhibitors PF-562271, NVP-
TAE226, and PF-573228 ex vivo. This resulted in significant
potentiation of cell killing at increasing concentrations of the
drugs (Figures 7B and S5B).
DISCUSSION
Here, we have examined large B-ALL cohorts to define the spec-
trum of IKZF1 alterations and used this to inform the develop-
ment of faithful mouse models of human Ph+ ALL. These models
incorporate modeling of ARF loss, the secondmost common ge-
netic alteration in Ph+ ALL, which has been shown to reduce the
latency of experimental Ph+ ALL, but has not previously been co-
modeled with IKZF1 alterations (Williams et al., 2006, 2007).
Importantly, we have studied Ikzf1 haploinsufficiency and
expression of IK6. In contrast to previously modeled Ikzf1 dele-
tions (Joshi et al., 2014), IK6 lacks all four N-terminal zinc fingers
required for normal DNA binding and arises from the most com-
mon focal IKZF1 deletion observed in human ALL.
Using these models and complementary genomic and prote-
omic approaches, we have shown that perturbation of IKZF1 ac-
tivity is a central event in the pathogenesis of BCR-ABL1
lymphoid leukemogenesis and reduced response to TKI therapy.
We show that Ikzf1 alterations induce a hematopoietic stem cell-
like gene expression program accompanied by upregulation of
adhesion molecules and signaling pathways that mediate
abnormal adherence. We provide evidence that Ikzf1 alterations
confer stem cell-like properties, as demonstrated by increased
single cell colony formation and induction of adhesion molecules
in mouse and human ALL.
Increased expression of THY1 (Yamazaki et al., 2009) and in-
tegrins (Hsieh et al., 2013; Miller et al., 2013) have been noted
previously in ALL and Ikzf1 mutant mouse B cells (Joshi et al.,
2014), but not in Ph+ ALL. In gain- and loss-of-function studies,
we have shown that upregulation of these genes is a conse-
quence of IKZF1 alterations and directly contributes to
enhanced adhesion and self-renewal properties in Ikzf1-altered
BCR-ABL1 cells. Moreover, we have shown that each adhesion
molecule is a direct transcriptional target of IKZF1, providing
a mechanism for deregulation of expression in IKZF1-mutant
leukemia.
The reversal of this phenotype with retinoids was striking and
emphasizes the utility of drug screens interrogating phenotypes
more complex than killing alone. Administration of retinoid ago-
nists resulted in profound reversal of the stem cell transcriptional
program, and abrogation of adherence and self-renewal, without
direct cytotoxicity. The Ikzf1 locus has multiple retinoid receptor
binding sites and, strikingly, retinoids selectively induced
expression of WT IKZF1 resulting in expression of IKZF1 target
genes. Using adhesion assays and calvarial imaging, we showedc.
Figure 7. Retinoids Potentiate TKI Therapy in BCR-ABL1 Leukemia
(A) WT C57Bl/6 mice were engrafted with Arf/ BCR-ABL1 MIG-IK6 or MIG cells and randomized to vehicle, bex, and/or dasatinib. On Kaplan-Meier analysis,
bex significantly increased survival time, with the greatest effect observed in mice treated with both drugs (**p < 0.005, *p < 0.05, and n = 5 mice per group).
(B) Dose-response curves of human BCR-ABL1 CDKN2A/B-deleted (i.e., INK4/ARF/), IKZF1 D4–7, IK6 + R502W mutation, or IK6 + D2–7 leukemic cells
harvested fromNSGmice and immediately treated ex vivo with increasing concentrations of bex, or ATRA at increasing concentrations of dasatinib. Each retinoid
inhibited cell proliferation, even at very low concentrations of dasatinib, reduced the TKI IC50 (n = 3 biological replicates performed in triplicate).
(C) Schematic summarizing effects of IKZF1 alterations and their reversal by retinoids.
See also Figure S5.
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that retinoids completely reversed the stromal adhesion of
IKZF1-altered leukemic cells. Together with the observation
that enforced IKZF1 expression also abrogated adhesion, these
findings suggest that retinoid-mediated induction of IKZF1
directly contributed to the reversal of stem cell features and
increased responsiveness to dasatinib in Ph+ ALL. The observed
induction of IKZF1 expression suggests that retinoids may have
less effect in the minority of ALL cases with biallelic alterations
resulting in complete loss of IKZF1 expression. However, in
contrast to enforced expression of IKZF1, retinoids induced dif-
ferentiation and cell cycle arrest independent of IKZF1 induction,
indicating that retinoids have both IKZF1 dependent and inde-
pendent effects in Ph+ ALL (Figure 7C).
Retinoids are approved for use in several diseases, including
all-trans-RA in acute promyelocytic leukemia (Park and Tall-
man, 2011) and bexarotene in cutaneous T cell lymphoma
(Connolly et al., 2013), but have not been previously systemat-
ically investigated in Ph+ ALL. Our findings provide a rationale
for clinical evaluation of these agents in IKZF1-altered Ph+
ALL. Collectively, these results indicate that IKZF1 alterations
have important roles in determining disease lineage, reduced
TKI sensitivity, and induction of stem cell features in Ph+
B-ALL and that disrupting these phenotypes by targeting the
retinoid pathway, or downstream signaling pathways, represent
important treatment opportunities that should be pursued in
clinical trials.
EXPERIMENTAL PROCEDURES
Mouse Modeling of BCR-ABL1 Leukemia
Forwhole BMexperiments, unmanipulatedBMwas transducedwith retrovirus
for 3 hr and one million unsorted cells were transplanted by tail vein injection
into lethally irradiated WT recipients. To derive pre-B cells, BCR-ABL1-trans-
ducedBMwas cultured in the absence of feeder layers or cytokines, cells were
subsequently transduced with retroviruses on retronectin, and 2 3 105 sorted
cells were injected by tail vein into sublethally irradiatedWT recipients. For lin
cell transplantation experiments, unmanipulated whole BM cells lacking line-
age markers were isolated and transduced with retroviruses prior to sorting
and injection into lethally irradiated WT recipients. Mice were housed in an
American Association of Laboratory Animal Care (AALAC)-accredited facility
and were treated on Institutional Animal Care and Use Committee (IACUC)-
approved protocols in accordance with NIH guidelines.
Analysis of Human Leukemias
Previously reported cohorts (Mullighan et al., 2007, 2008, 2009; Roberts et al.,
2012, 2014) and 98 adult B-ALL samples collected on the Eastern Cooperative
Oncology Group E2993 (Rowe et al., 2005) and ClinicalTrials.gov identifier
NCT00002514 and Alliance for Clinical Oncology C10403 (https://
clinicaltrials.gov NCT00558519) studies were analyzed for IKZF1 deletions
and mutations by SNP 6.0 microarrays (Affymetrix) and by genomic PCR
and Sanger Sequencing as previously described (Mullighan et al., 2007,
2009; Mullighan, 2011). All samples were obtained with patient or parent/
guardian provided informed consent under protocols approved by the Institu-
tional Review Board at each Children’s Oncology Group (COG) and Eastern
Cooperative Oncology Group (ECOG) institution and St. Jude Children’s
Research Hospital. All samples were deidentified prior to analysis.
Statistical Analyses
Data analyses were performed using GraphPad Prism Version 6.0 (GraphPad).
All data are presented as mean ± SD. Significance was determined using
Student’s t test, ANOVA, or Mantel-Cox log rank test as appropriate. For sur-
vival studies, Kaplan-Meier curves were generated and Mantel-Cox p values
were determined for pairwise comparisons of cohorts. A p value of less than
0.05 was considered significant.354 Cancer Cell 28, 343–356, September 14, 2015 ª2015 Elsevier InOther Procedures
All methods are described in detail in the Supplemental Information.
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